Navigation Links
Precision Therapeutics Demonstrates Utility of Multi-Gene Predictors in Predicting Chemotherapy Response for Breast Cancer Patients
Date:6/6/2011

PITTSBURGH, June 6, 2011 /PRNewswire/ -- Precision Therapeutics, Inc. demonstrated data supporting the utility of cell line-derived multi-gene predictors in the prediction of preoperative chemotherapy response in early stage breast cancer at the 2011 ASCO Annual Meeting on June 4, 2011 in Chicago, Illinois.  The study, titled, Multigene Predictors Developed on Breast Cancer Cell Lines to Predict Patient Chemotherapy Response:  A Validation Study on the NSABP B-27 Trial, combined the genomic profiles of cell lines with their in vitro chemoresponse data to identify genes whose expression was associated with drug response.  The resulting MGP was used to predict chemotherapy response in patients.

"Clinical interests currently lie in identifying patients most responsive to specific chemotherapy agents to maximize the benefit of treatment and to minimize unnecessary side effects," stated Kui Shen, Ph.D., a bioinformatics scientist and co-author of the study. "By combining ChemoFx® chemosensitivity data from cell lines with their genomic profiles, Precision has developed a procedure to derive gene signatures that may predict a patient's chemotherapy response prior to treatment. This approach is now confirmed using NSABP B-27 clinical data, showing an accuracy of as high as 75%."

Precision continues to seek and develop strategic products that fit within the cancer care continuum, including multi-gene predictors to help with choosing treatments for triple negative women.  Precision has completed 12 separate validations including both NSABP and U.S. Oncology trials.

About Precision Therapeutics

Precision Therapeutics, a leading life-science company based in Pittsburgh, Pennsylvania, is dedicated to personalized cancer care.  Precision offers a portfolio of products developed to help guide physicians and patients with difficult clinical decisions throughout the cancer care continuum.

Precision's state of the art bioinformatics combined with the analysis of the live molecular, proteomic and genomic activity of each patient's cancer offer an innovative foundation for further development and commercialization of novel predictive markers for cancer therapy. 

About ChemoFx®

Precision's first commercial test, ChemoFx®, is a proprietary drug response marker which measures an individual's malignant tumor response to a range of standard therapeutic alternatives under consideration by a physician. For more information, please visit www.precisiontherapeutics.com, or www.chemofx.com.


'/>"/>
SOURCE Precision Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. TechPrecision Corporation Receives $1.6 Million in New Orders from Existing Customers
2. Volcano to Highlight its Precision Guided Therapy Technologies at EuroPCR
3. Robotic Couch Provides Extra Degree of Precision for Patients Undergoing Radiation Therapy for Cancer
4. Boston Scientific Receives FDA Approval of New Clik(TM) Anchor for Precision Plus(TM) Spinal Cord Stimulator System
5. Source Precision Medicine, Inc. d/b/a Source MDx Announces Foundational Patents Will Be Offered for Sale on April 29, 2011
6. Source Precision Medicine, Inc., dba SourceMDx Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. of the firm of Finn, Warnke & Gayton, LLP
7. Applied Precision Exhibit at the Biophysical Society Annual Meeting Showcases New Microscopy Solutions for Life Science Industries
8. TechPrecision Corporation Receives New $450,000 Medical Purchase Order
9. Applied Precision Scientific Team to Present 3D-SIM Paper at BiOS in San Francisco
10. Abbott Diabetes Care Announces Recall of Certain Lots of Precision Xtra®, Precision Xceed Pro®, MediSense® Optium™, Optium™, OptiumEZ and ReliOn® Ultima Blood Glucose Test Strips in the United States and Puerto Rico
11. Exempla Saint Joseph Hospital Commences Treating Cancer Patients Using New TrueBeam™ System for High-Precision Image-Guided Radiotherapy and Radiosurgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/13/2017)... Sept. 13, 2017   OrthoAtlanta has been named ... Football Host Committee (AFHC) for the 2018 College Football Playoff ... 2018, at Mercedes-Benz Stadium in Atlanta, Georgia ... AFHC "I,m In" campaign, participating in many activities leading up ... ...
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., ... Solutions (VLMS), is pleased to announce the appointment ... member of its Board of Directors and Chairman ... VLMS enables life science companies to manage their ... use of paper in this process. Furthermore, ValGenesis ...
(Date:9/9/2017)...  Eli Lilly and Company (NYSE: LLY ... for lasmiditan, an investigational, oral, first-in-class molecule for the ... compared to placebo in the Phase 3 SPARTAN study. ... Congress of the International Headache Society (IHC) in ... today demonstrate lasmiditan,s potential to reduce pain and provide ...
Breaking Medicine Technology:
(Date:9/21/2017)... ... September 21, 2017 , ... SABRE is raising awareness about personal ... to the end of November. , The Chicago, Illinois, based self-defense brand has been ... them about the ease of taking their personal safety into their own hands. , ...
(Date:9/21/2017)... ... September 21, 2017 , ... Promotional ... http://www.fdanews.com/products/54818-promotional-communication      , In the competitive world of drug and device marketing ... in compliance with FDA rules. , The FDA has issued two draft guidances ...
(Date:9/21/2017)... ... September 21, 2017 , ... Demonstrating a consistent and continued ... have been awarded five-year accreditation status through the Public Health Accreditation Board ... by a PHAB-accredited health department now extend to more than 203 million ...
(Date:9/21/2017)... ... September 21, 2017 , ... In addition to sticking with ... more holistic approach and use natural alternatives for all house cleaning products, disinfectants, ... USDA guaranteeing that, the new line of essential oils, are all 100% organic ...
(Date:9/21/2017)... ... 2017 , ... The New England Center for Children® (NECC®), a global leader ... Hung to the Board of Directors. , “The New England Center for Children ... an invaluable addition to our team,” said Vincent Strully, Jr., President and CEO of ...
Breaking Medicine News(10 mins):